EO7 Stock Overview A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Endo International Historical stock prices Current Share Price €0.01 52 Week High €0.14 52 Week Low €0.0002 Beta 0.80 1 Month Change 400.00% 3 Month Change 0% 1 Year Change -88.89% 3 Year Change -99.79% 5 Year Change -99.86% Change since IPO -99.99%
Recent News & Updates
Endo International plc to Report Q1, 2024 Results on May 30, 2024 May 17 Fourth Amended Reorganization Plan Filed by Endo International plc Mar 20
Endo International plc to Report Q3, 2023 Results on Nov 06, 2023 Nov 07
Endo International plc, Annual General Meeting, Sep 07, 2023 Aug 16 Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection
Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture Jun 28 See more updates
Endo International plc to Report Q1, 2024 Results on May 30, 2024 May 17 Fourth Amended Reorganization Plan Filed by Endo International plc Mar 20
Endo International plc to Report Q3, 2023 Results on Nov 06, 2023 Nov 07
Endo International plc, Annual General Meeting, Sep 07, 2023 Aug 16 Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection
Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture Jun 28
Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe Jun 13 Two Affiliate Companies Joined Endo International plc Bankruptcy May 27
Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023
Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool Oct 28 Nasdaq to Delist Common Stock of Endo International Sep 15
Endo International Provides Delisting Update Aug 30
Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index Aug 24 Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index Endo International plc Filed for Bankruptcy Aug 18
Endo International plc Filed for Bankruptcy Aug 17
Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021) Aug 12 Endo International Receives Non-Compliance Notice from Nasdaq Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index Jun 21
First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.20 profit in 1Q 2021) May 07
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting May 06
Endo International plc to Report Q1, 2022 Results on May 05, 2022 Apr 13
Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors Mar 31
Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials Mar 29
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Investor sentiment improved over the past week Feb 11
Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles Feb 08
Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism Jan 14
Investor sentiment deteriorated over the past week Dec 22
Investor sentiment deteriorated over the past week Dec 08
Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting Nov 24
Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020) Nov 05
Investor sentiment improved over the past week Nov 03
Investor sentiment improved over the past week Oct 12
Investor sentiment improved over the past week Sep 27
Investor sentiment improved over the past week Sep 11
Investor sentiment deteriorated over the past week Aug 13
Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020) Aug 06
Investor sentiment improved over the past week Jul 24
Investor sentiment deteriorated over the past week Jul 09 Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index
Chairman Paul Campanelli has left the company Jun 15
Senior Independent Director Roger Kimmel has left the company Jun 15
Investor sentiment improved over the past week May 18
First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020) May 08 Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021
Investor sentiment deteriorated over the past week Apr 11
Independent Director recently sold €125k worth of stock Mar 16
Investor sentiment deteriorated over the past week Mar 05
Full year 2020 earnings released: EPS US$1.08 (vs US$1.60 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
Endo International plc Appoints Jennifer M. Chao as Director, Audit Committee and its Compliance Committee Feb 18
New 90-day high: €7.46 Feb 03 Endo International plc(NasdaqGS:ENDP) dropped from S&P 500 - Pharmaceuticals (Industry)
Endo International plc to Report Q4, 2020 Results on Feb 25, 2021 Jan 27
New 90-day high: €5.26 Dec 28
Endo International plc (NasdaqGS:ENDP) completed the acquisition of BioSpecifics Technologies Corp. (NasdaqGM:BSTC) from Edwin H. Wegman Marital Trust, Renaissance Technologies Corp., BlackRock, Inc. (NYSE:BLK). Dec 03
Morganti & Co., P.C. Announce the Settlement Approval of the Endo International plc Securities Class Action Nov 13
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.30 loss per share Nov 07
Endo International plc Revised Revenues Guidance for the Full Year of 2020 Nov 06
New 90-day high: €4.87 Oct 27
Endo International plc (NasdaqGS:ENDP) entered into an Agreement and Plan of Merger to acquire BioSpecifics Technologies Corp. (NasdaqGM:BSTC) from Edwin H. Wegman Marital Trust, Renaissance Technologies Corp., BlackRock, Inc. (NYSE:BLK) and others for approximately $650 million. Oct 20
Endo International Plc's Aesthetics Data to Be Featured in Five Presentations At the American Society for Dermatologic Surgery's Annual Meeting Oct 11
Endo International plc to Report Q3, 2020 Results on Nov 05, 2020 Oct 08
New 90-day high: €3.47 Oct 06
Endo International plc to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology Sep 25 Endo International plc (NasdaqGS:ENDP) completed the acquisition of Par Pharmaceutical Holdings, Inc. from TPG Biotechnology Partners IV, L.P., fund of TPG Biotech and others.
New 90-day low - €2.33 Sep 10
New 90-day low - €2.66 Aug 13
First half earnings released Aug 07
An undisclosed buyer acquired an unknown stake in Endo International plc (NasdaqGS:ENDP) from TPG Capital, L.P. Jul 30 Shareholder Returns EO7 DE Pharmaceuticals DE Market 7D 0% 1.7% 0.3% 1Y -88.9% -16.3% 6.9%
See full shareholder returns
Return vs Market: EO7 underperformed the German Market which returned 2.5% over the past year.
Price Volatility Is EO7's price volatile compared to industry and market? EO7 volatility EO7 Average Weekly Movement 214.0% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EO7's share price has been volatile over the past 3 months.
Volatility Over Time: EO7's weekly volatility has increased from 144% to 214% over the past year.
About the Company Founded Employees CEO Website 1997 2,931 Blaise Coleman www.endo.com
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Show more Endo Inc. Fundamentals Summary How do Endo International's earnings and revenue compare to its market cap? EO7 fundamental statistics Market cap €141.13k Earnings (TTM ) -€2.28b Revenue (TTM ) €1.87b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EO7 income statement (TTM ) Revenue US$2.01b Cost of Revenue US$941.90m Gross Profit US$1.07b Other Expenses US$3.52b Earnings -US$2.45b
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -10.41 Gross Margin 53.17% Net Profit Margin -121.69% Debt/Equity Ratio -123.5%
How did EO7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/05/03 15:14 End of Day Share Price 2024/05/03 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Richard Silver Barclays Gary Nachman BMO Capital Markets Equity Research Sumant Satchidanand Kulkarni BofA Global Research
Show 41 more analysts 
